RBC Capital analyst Brian Abrahams downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Inc trading resumes
- Neumora Therapeutics Inc trading halted, volatility trading pause
- Neumora trial failure a ‘big blow’ to bull case, says Stifel
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Neumora down 82% after saying navacaprant did not meet primary endpoint